查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1983163

肝炎治疗市场：依药物类别、疾病类型、给药途径、通路和地区划分

Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格
简介目录

据估计，2026年肝炎治疗市场规模为263.8亿美元，预计2033年将达到329.06亿美元。预计2026年至2033年，该市场将以3.2%的复合年增长率成长。

报告范围 报告详情
基准年： 2025 2026年市场规模： 263.8亿美元
历史数据时期： 2020年至2024年 预测期： 2026年至2033年
2026年至2033年预测期间的复合年增长率： 3.20% 2033年市场规模预测： 329.06亿美元

肝炎是指肝臟的发炎性疾病。肝炎是由病毒感染引起的肝臟感染疾病，包括甲型、B型、丙型、丁型和戊型肝炎。甲型肝炎是一种急性、短期疾病，而B型、C型和丁型肝炎则为持续性疾病，且极易发展为慢性疾病。戊型肝炎通常为急性，但对孕妇尤其危险，可能增加孕产妇和胎儿的死亡率和发病率。

市场动态

全球肝炎盛行率的上升预计将推动肝炎治疗市场的成长。根据世界卫生组织（世卫组织）统计，2015年全球有2.57亿人患有慢性B型肝炎，2016年新增乙型肝炎病例450万例（占总人口的16.7%）。乙型肝炎可透过安全有效的疫苗预防。此外，世卫组织的目标是到2030年消除病毒性肝炎，其中包括将全球新感染病例减少90%，并将病毒性肝炎死亡人数减少65%。

然而，肝炎治疗药物研发和核准所需的时间等因素预计将在预测期内阻碍肝炎治疗市场的成长。例如，根据美国国家生物技术资讯中心 (NCBI) 2017 年的一份报告，从标靶识别到上市核准，一种新肝炎药物的研发需要超过 12 年的时间。

本次调查的主要特点。

  • 本报告对肝炎治疗市场、市场规模以及 2026 年至 2033 年的预测期内的复合年增长率 (%) 进行了详细分析，以 2025 年为基准年。
  • 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
  • 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
  • 本报告根据以下参数对全球肝炎治疗市场的主要企业进行了分析：公司概况、财务表现、产品系列、地理企业发展、分销策略、关键发展和策略。
  • 透过利用本报告中的见解，企业行销负责人和经营团队可以就未来的产品发布、政府倡议、技术升级、市场扩张和行销策略做出明智的决策。
  • 本报告面向该行业的众多相关人员，包括投资者、产品製造商、经销商、供应商、研究和咨询公司、新参与企业和金融分析师。

目录

第一章：研究目标与前提条件

  • 研究目标
  • 前提
  • 简称

第二章 市场概览

  • 报告摘要
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 主要进展
  • 监理情势
  • 流行病学分析
  • 救赎方案
  • PEST分析

第四章 全球肝炎治疗药物市场：依药物类别划分，2026-2033年

  • α干扰素
  • HIV NRTI
  • 核苷酸聚合酵素/NS5A抑制剂的组合药物
  • 丙型肝炎蛋白酶/NS5A抑制剂组合药物
  • NS5A抑制剂
  • 核苷酸聚合酵素抑制剂
  • 核苷类似物抗病毒药物
  • 血小板生成刺激剂

第五章 全球肝炎治疗市场：依疾病类型划分，2026-2033年

  • B型肝炎
  • C型肝炎
  • 其他的

第六章 全球肝炎治疗市场：依给药途径划分，2026-2033年

  • 口服
  • 注射

第七章 全球肝炎治疗药物市场：依通路划分，2026-2033年

  • 医院药房
  • 零售药房
  • 网路药房

第八章 全球肝炎治疗市场：依地区划分，2026-2033年

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 法国
    • 西班牙
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • ASEAN
    • 澳洲
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 非洲
    • 北非
    • 中非
    • 南非
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家

第九章 竞争情势

  • 公司简介
    • Merck &Co. Inc.
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC.
    • Cipla Inc.

第十章

  • 参考
  • 调查方法
简介目录
Product Code: CMI2977

Hepatitis Drugs Market is estimated to be valued at USD 26,380 Mn in 2026 and is expected to reach USD 32,906 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.2% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 26,380 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 3.20% 2033 Value Projection: USD 32,906 Mn

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study

  • This report provides in-depth analysis of the hepatitis drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

  • Drug Class Insights (Revenue, USD Mn, 2026 - 2033)
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
  • Disease Type Insights (Revenue, USD Mn, 2026 - 2033)
    • Hepatitis B
    • Hepatitis C
    • Others
  • Route of Administration Insights (Revenue, USD Mn, 2026 - 2033)
    • Oral
    • Injection
  • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Mn, 2026 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Merck & Co. Inc.
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • Hoffmann-La Roche Ltd.
    • LAURUS Labs, Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC.
    • Cipla Inc

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Epidemiology Analysis
  • Reimbursement Scenario
  • PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2026-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Interferon Alphas
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • HIV NRTIs
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hepatitis C Protease / NS5A Inhibitor Combinations
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • NS5A Inhibitors
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Nucleotide Polymerase Inhibitors
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Nucleoside Analogue Antivirals
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Thrombopoiesis Stimulating Agents
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

5. Global Hepatitis Drugs Market, By Disease Type, 2026-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hepatitis B
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hepatitis C
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Others
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

6. Global Hepatitis Drugs Market, By Route of Administration, 2026-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Oral
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Injection
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

7. Global Hepatitis Drugs Market, By Distribution Channel, 2026-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hospital Pharmacies
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Retail Pharmacies
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Online Pharmacies
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends

8. Global Hepatitis Drugs Market, By Region, 2026-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 - 2033
  • North America
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • U.S.
      • Canada
  • Europe
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • China
      • Japan
      • India
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Africa
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • North Africa
      • Central Africa
      • South Africa
  • Middle East
    • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
    • Y-o-Y Growth Analysis, For Country, 2021 - 2033
    • Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Merck & Co. Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead Sciences Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AbbVie Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bristol Myers Squibb Company
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • LAURUS Labs
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Zydus Cadila
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hetero Healthcare Limited
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlaxoSmithKline PLC.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Cipla Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
      • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact